GHO Capital acquires Scientist.com to scale AI R&D orchestration.

GHO Capital Partners LLP has closed its acquisition of Scientist.com, beginning a growth push to expand the life‑science marketplace’s AI orchestration capabilities and international footprint. Financial terms were undisclosed, but the deal positions the platform to accelerate automation across outsourced drug discovery and development.

Founded in 2007, Scientist.com has migrated from a procurement marketplace into an AI‑enabled R&D orchestration product that links biopharma teams with more than 6,000 pre‑vetted research suppliers. The platform digitizes vendor selection, contracting, compliance tracking and spend visibility — areas where sponsors increasingly seek faster cycle times and lower operational risk.

Management stressed continuity: founders and executives Kevin Lustig (CEO) and Chris Petersen (CTO) will remain at the helm while working with GHO to scale engineering and sales across Europe and other international markets. On the private equity side, Edward de Nor and Stuart Quin, partners at GHO Capital Partners LLP, said the firm will back product development focused on intelligent vendor management, automated contracting and predictive project modeling.

The transaction sits at the intersection of two larger trends. First, life‑science companies are outsourcing more R&D functions: industry estimates put the outsourced research and contract services market well above the tens of billions of dollars, growing at mid‑single‑digit CAGRs as drug development complexity increases. Second, buyers are applying AI and data to tame supplier networks and compress timelines — a capability Scientist.com already markets to major pharma and hundreds of biotech customers.

From an investor perspective, GHO Capital brings sector specialization and scale — the firm manages roughly $10 billion in healthcare assets and focuses on growth in BioPharma Services, HealthTech and Life‑Science Tools. The combination of a niche PE investor and a platform company reflects a common mid‑market playbook: invest in product development, expand international sales operations and pursue tuck‑ins or partnerships to deepen category leadership.

Operationally the business will remain headquartered in Solana Beach, California, and continue serving enterprise private marketplaces and direct customers worldwide. With this backing, Scientist.com aims to turn fragmented outsourced R&D supply chains into a more automated, data‑driven flow — a bet that aligns with buyers’ growing appetite for speed, transparency and predictable outcomes in drug development.